identification of circulating micrornas for the differential diagnosis of parkinson’s disease and multiple system atrophy.

Clicks: 394
ID: 155517
2014
Free PDF
Article Quality & Performance Metrics
Overall Quality
Not rated
Combines reader engagement with the AI quality analysis. This article has not been analysed, so there is no overall score — reader engagement is measured and shown alongside.
AI Quality Assessment
Not analyzed
Readership in this journal
Steady

Ranked #28 of 398 articles by views in macromolecular bioscience

Most read Least read

Bar heights use a square-root scale. Only the 120 most-read articles are drawn; the journal has 398 in total.

Mint this article as an NFT
Not yet minted

Create a permanent, verifiable on-chain record of this article on the Scimatic Network. The NFT is held in your Journament account, and you can withdraw it to your own wallet at any time.

5 SUSD one-off · no wallet required
Sign in to mint
Abstract
Background. Parkinson's disease (PD) is a progressive neurodegenerative disorder which may be misdiagnosed with atypical conditions such as Multiple System Atrophy (MSA), due to overlapping clinical features. MicroRNAs (miRNAs) are small noncoding RNAs with a key role in post-transcriptional gene regulation. We hypothesized that identification of a distinct set of circulating miRNAs (cmiRNAs) could distinguish patients affected by PD from MSA and healthy individuals. Results. Using TaqMan Low Density Array technology, we analysed 754 miRNAs and found 9 cmiRNAs differentially expressed in PD and MSA patients compared to healthy controls. We also validated a set of 4 differentially expressed cmiRNAs in PD and MSA patients versus controls. More specifically, miR-339-5p was downregulated, whereas miR-223*, miR-324-3p and mir-24 were upregulated in both diseases. We found cmiRNAs specifically deregulated in PD (downregulation of miR-30c and miR-148b) and in MSA (upregulation of miR-148b). Finally, comparing MSA and PD, we identified 3 upregulated cmiRNAs in MSA serum (miR-24, miR-34b, miR-148b). Conclusions. Our results suggest that cmiRNA signatures discriminate PD from MSA patients and healthy controls and may be considered specific, non-invasive biomarkers for differential diagnosis.
Reference Key
evallelunga2014frontiersidentification Use this key to autocite in the manuscript while using SciMatic Manuscript Manager or Thesis Manager
Authors Annamaria eVallelunga, Marco eRagusa, Stefania eDi Mauro, Tommaso eIannitti, Manuela ePilleri, Roberta eBiundo, Luca eWeis, Cinzia eDi Pietro, Angela eDe Iuliis, Alessandra eNicoletti, Mario eZappia, Michele ePurrello, Angelo eAntonini
Are you one of these authors? Claim your profile
Journal macromolecular bioscience
Year 2014
DOI
10.3389/fncel.2014.00156
URL
http://journal.frontiersin.org/Journal/10.3389/fncel.2014.00156/full
Keywords
parkinson’s disease micrornas multiple system atrophy early diagnosis neuropsychiatry biological psychiatry

Citations

No citations found. To add a citation, contact the admin at info@scimatic.org

Comments

No comments yet. Be the first to comment on this article.